Inactivation of the Hepatic Cytochrome P450 System by Conditional Deletion of Hepatic Cytochrome P450 Reductase
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Cytochrome P450 (CYP) monooxygenases catalyze the oxidation of a large number of endogenous compounds and the majority of ingested environmental chemicals, leading to their elimination and often to their metabolic activation to toxic products. This enzyme system therefore provides our primary defense against xenobiotics and is a major determinant in the therapeutic efficacy of pharmacological agents. To evaluate the importance of hepatic P450s in normal homeostasis, drug pharmacology, and chemical toxicity, we have conditionally deleted the essential electron transfer protein, NADH:ferrihemoprotein reductase (EC, cytochrome P450 reductase, CPR) in the liver, resulting in essentially complete ablation of hepatic microsomal P450 activity. Hepatic CPR-null mice could no longer break down cholesterol because of their inability to produce bile acids, and whereas hepatic lipid levels were significantly increased, circulating levels of cholesterol and triglycerides were severely reduced. Loss of hepatic P450 activity resulted in a 5-fold increase in P450 protein, indicating the existence of a negative feedback pathway regulating P450 expression. Profound changes in the in vivo metabolism of pentobarbital and acetaminophen indicated that extrahepatic metabolism does not play a major role in the disposition of these compounds. Hepatic CPR-null mice developed normally and were able to breed, indicating that hepatic microsomal P450-mediated steroid hormone metabolism is not essential for fertility, demonstrating that a major evolutionary role for hepatic P450s is to protect mammals from their environment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, these mice had hepatomegaly, accumulated hepatic lipids, and had a 99% decrease in bile acids, 65% decrease in serum cholesterol, and 50% decrease in serum triglycerides.”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [312]
In the citing paper
“By contrast, liver-specific POR knockout mice created by cre/lox technology were grossly normal-developing, growing, and living as long as normal mice, and having normal reproductive capacity, indicating normal gonadal P450 function (312,313).”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [312]
In the citing paper
“Furthermore these animals had dramatically decreased capacities to metabolize acetaminophen, phenobarbital, and testosterone despite having a 5-fold increase in total hepatic P450 content.”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [312]
In the citing paper
“Liver-specific knockout of POR in mice decreases the activities of hepatic drug-metabolizing enzymes (312, 313), thereby potentially rendering some drugs teratogenic.”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [312]
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834
P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature
Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199602000-00002 · Cited by 2,945
Conney, A. H. (1982) · PubMed · Cited by 1,557
Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. D., Lindner, J., Cherrington, A. D., & Magnuson, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.305 · Cited by 1,302
Self-citationHayhurst, G. P., Lee, Y.-H., Lambert, G., Ward, J. M., & Gonzalez, F. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.4.1393-1403.2001 · Cited by 1,107
Shimano, H., Horton, J. D., Hammer, R. E., Shimomura, I., Brown, M. S., & Goldstein, J. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118951 · Cited by 816
The Role of Orphan Nuclear Receptors in the Regulation of Cholesterol Homeostasis
Repa, J. J., & Mangelsdorf, D. J. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.459 · Cited by 759
Role of CYP2E1 in the Hepatotoxicity of Acetaminophen
Lee, S. S. T., Buters, J. T. M., Pineau, T., Fernandez-Salguero, P., & Gonzalez, F. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.20.12063 · Cited by 656
Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat
Spady, D. K., & Dietschy, J. M. (1983) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37999-2 · Cited by 411
Research works printed but not linked: 4
- Pikuleva, 1999, Mol. Aspects Med., 20, 33
- Henderson, 1992, 10, 221
- Hines, 2001, Drug Metab. Dispos., 29, 623
- Conney, 1982, Cancer Res., 42, 4875
Cited by
Items 201–257 of 257
Cheng, X., Gu, J., & Klaassen, C. D. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.060053 · Cited by 9
“2, the mRNA of some P450s, such as Cyp2b10, 3a11 and 4a14, which are hallmark target genes of CAR, PXR, and peroxisome proliferator-activated receptor a (PPARa) signaling, respectively, are markedly increased in livers of H-Cpr-null mice.”
BackgroundInfluentialLi, Y., Zhang, C., & Zhang, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1019696 · Cited by 9
“Additionally, PORD may account for reduced hepatic drug metabolization (30).”
BackgroundIn vivo selection of hepatocytes
Vonada, A., & Grompe, M. (2024) · Hepatology · doi:10.1097/hep.0000000000001143 · Cited by 9
Bapiro, T. E., Martin, S. W., Blacker, T. S., Wilkinson, S. D., Orton, A. L., Hariparsad, N., Jones, R. D. O., Duchen, M. R., & Harlfinger, S. (2025) · Communications Biology · doi:10.1038/s42003-025-08903-1 · Cited by 8
MacLeod, A. K., Fallon, P. G., Sharp, S., Henderson, C. J., Wolf, C. R., & Huang, J. T.-J. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.043661 · Cited by 9
“tocyte specific P450 reductase null (HRN) mouse (26).”
BackgroundResultSelf-citationHuman P450 Oxidoreductase Deficiency
Flück, C. E., & Pandey, A. V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64966-8 · Cited by 12
Pleiotropy of Progesterone Receptor Membrane Component 1 in Modulation of Cytochrome P450 Activity
Barata, I. S., Rueff, J., Kranendonk, M., & Esteves, F. (2024) · Journal of Xenobiotics · doi:10.3390/jox14020034 · Cited by 8
“…central functions, knockout (KO) of the POR gene (encoding CPR) is embryonically lethal in mice [75,76], while liver-specific POR KO mice developed normally and were able to breed, albeit demonstrating compromised drug metabolism and bile acid production, and increased hepatic lipid levels [77].”
BackgroundBurke, R. S., Somasuntharam, I., Rearden, P., Brown, D., Deshmukh, S. V., DiPietro, M. A., DiMuzio, J. M., Eisenhandler, R., Fauty, S. E., Gibson, C. R., et al. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1433-0 · Cited by 7
Luan, Y., Xing, G., Qi, X., Wu, M.-J., Li, C., Yao, J., Gong, L., Nohmi, T., Gu, J., Zhou, W., et al. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0891-6 · Cited by 7
P450 Oxidoreductase Deficiency (PORD)
Flück, C. E., & Pandey, A. V. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416006-4.00010-7 · Cited by 11
Cheng, X., Zhang, Y., & Klaassen, C. D. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.216796 · Cited by 7
“Discussion H-Cpr-null mice have a 65% reduction in serum cholesterol and a 90% decrease in gallbladder bile volume (Henderson et al., 2003), leading to a reasonable hypothesis that the amount of BAs would be severely reduced in H-Cpr-null mice due to the loss of function of the Cpr-dependent BA…”
BackgroundResultInfluentialCytochrome b5 Binds Tightly to Several Human Cytochrome P450 Enzymes
Kim, D., Kim, V., Tateishi, Y., & Guengerich, F. P. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000475 · Cited by 7
“This NADH-dependent electron transport system may be how drug metabolism occurs in liver-specific NADPH-P450 reductase (POR) knockout (Por –/– ) mice (Gu et al., 2003; Henderson et al., 2003).”
BackgroundStringer, R. A., Ferreira, S., Rose, J., & Ronseaux, S. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.070151 · Cited by 6
“The HRN mouse only has residual hepatic P450 activity as a result of a liver-specific knockout of the P450 reductase enzyme during the postnatal period (Henderson et al., 2003), and extrahepatic P450 is unaffected.”
BackgroundAkingbasote, J. A., Foster, A. J., Wilson, I. D., Sarda, S., Jones, H. B., & Kenna, J. G. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1505-x · Cited by 6
The Principles, Enzymes, and Pathways of Human Steroidogenesis
Auchus, R. J., & Miller, W. L. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00096-4 · Cited by 6
Yamazaki, K., Kubara, K., Sugahara, G., Muto, H., Yamamoto, M., Mano, Y., Mitsuhashi, K. O., Yamasaki, C., Ishida, Y., Tateno, C., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101466 · Cited by 6
“30 Notably, liver-specific KO of Por yields seemingly normal mice, 19,31,32 suggesting that lethality is due to a lack of electron transport to the extrahepatic P450 enzymes.”
The First Defect in Electron Transfer to Mitochondrial P450 Enzymes
Miller, W. L., & Chung, B. (2016) · Endocrinology · doi:10.1210/en.2016-1044 · Cited by 5
Discrimination of haptens from prohaptens using the metabolically deficient Cprlow/low mouse
Chipinda, I., Blachère, F. M., Anderson, S. E., & Siegel, P. D. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.02.018 · Cited by 5
Disorders of sterol biosynthesis
Furtado, L. V., Kelley, R. I., & Opitz, J. M. (2016) · Translational Science of Rare Diseases · doi:10.3233/trd-160004 · Cited by 6
Genetic Variations in NADPH-CYP450 Oxidoreductase in a Czech Slavic Cohort
Tomková, M., Panda, S. P., Šeda, O., Baxová, A., Hůlková, M., Masters, B. S. S., & Pavel Martasek, E. (2015) · Pharmacogenomics · doi:10.2217/pgs.14.169 · Cited by 6
“Liverspecific knockout of Por generates phenotypically normal mice with seriously affected hepatic drug metabolism [21].”
BackgroundSaniova, B., Krkoska, D., Taziarova, M., Duris, M., Kalavska, A., Gulasova, I., Shahum, A., & Krcmery, V. (2013) · PubMed · Cited by 4
Fang, C., Bolivar, V. J., Gu, J. H., Yang, W., Zeitlin, S. O., & Ding, X. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.05.027 · Cited by 4
“…liver-Cpr-null, lung-Cpr-null, cardiomyocyte-Cpr-null, and intestinal epithelium-Cpr-null (Conroy et al., 2010; Fang et al., 2008; Gu et al., 2003; Henderson et al., 2003; Weng et al., 2007; Zhang et al., 2009) are generally viable and thus suitable for in vivo studies on the combined functions…”
BackgroundBoggs, J. W., Hop, C. E. C. A., McNamara, E., Deng, Y., Messick, K., West, K. A., & Choo, E. F. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400556x · Cited by 4
Clark, C., Pokhrel, M., Arthur, B., Suresh, P., Ates, I., Gibson, J., Dhungana, A., Mehlem, R., Boysia, A., Padalkar, M. V., et al. (2025) · Biology · doi:10.3390/biology14081091 · Cited by 3
“The histology and lipid results in the Ldlr − / − recipient mice selected with APAP are similar to the hepatic Cypor-null and Cypor-low mouse strains characterized in [39–41].”
A Novel POR G88S Mutation Causes Severe PORD and Establishes a Critical Pharmacogenomic Risk Profile
Velazquez, M. N. R., Dacal, J. L., Jørgensen, F. S., Sanguineti, N., Sharma, K., Marino, R. M., Garrido, N. P., Vaiani, E., Ramírez, P., Scaglia, P. A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf630 · Cited by 4
Drug–drug interactions in targeted cancer therapies: a focus on tyrosine kinase inhibitors
Stromatt, J. C., Chowdhury, A. T., Huang, K. M., Hu, S., Sparreboom, A., Baker, S. D., & Eisenmann, E. D. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2606258 · Cited by 3
Hill, L., Chaplain, M. A. J., Wolf, C. R., & Kapelyukh, Y. (2015) · Mathematical Medicine and Biology A Journal of the IMA · doi:10.1093/imammb/dqv029 · Cited by 3
Self-citationGray, N., Gethings, L. A., Plumb, R. S., & Wilson, I. D. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113318 · Cited by 4
Guo, Z., Yu, X., Fang, Z., Yang, K. G., Liu, C., Dong, Z., & Liu, C. (2024) · General Physiology and Biophysics · doi:10.4149/gpb_2023042 · Cited by 3
P450 oxidoreductase deficiency
Flück, C. E., Velazquez, M. N. R., & Pandey, A. V. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821424-4.00012-5 · Cited by 4
Akingbasote, J. A., Foster, A. J., Jones, H. B., David, R. M., Gooderham, N. J., Wilson, I. D., & Kenna, J. G. (2016) · Toxicology Research · doi:10.1039/c6tx00376a · Cited by 2
The Principles, Enzymes, and Pathways of Human Steroidogenesis
Auchus, R. J., & Miller, W. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00097-4 · Cited by 3
Reed, L., Indra, R., Mrízová, I., Moserová, M., Schmeiser, H. H., Wolf, C. R., Henderson, C. J., Stiborová, M., Phillips, D. H., & Arlt, V. M. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.01.020 · Cited by 2
Self-citationVariability in Induction of Human Drug Metabolizing Enzymes
Okey, A. B. (2005) · Drugs and the pharmaceutical sciences · doi:10.1201/9780849359507.ch6 · Cited by 2
Moural, T. W., Ban, L., Hernandez, J. A., Wu, M., Zhao, C., Palli, S. R., Alyokhin, A., & Zhu, F. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.29.318634 · Cited by 5
“3), indicating cytochrome P450-mediated detoxification is responsible for imidacloprid resistance in CPB. Inactivating microsomal P450s (Henderson et al., 2003) through the inhibition or silencing of CPR, offers a unique way to decipher contributions of P450s in adaptation to one or multiple…”
BackgroundGenetically Modified Mouse Models in ADME Studies
Jiang, X.-L., & Yu, A. (2012) · Wiley eBooks · doi:10.1002/9781118180778.ch28 · Cited by 1
Henderson, C. J., Scheer, N., & Wolf, C. R. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2.2.105 · Cited by 1
Self-citationMackenzie, N. C. W., Lillico, S. G., Brown, K., Wolf, C. R., & Whitelaw, C. B. (2010) · PubMed Central · Cited by 2
Self-citationMetabonomics in Understanding Drug Metabolism and Toxicology
Wen, B. (2012) · Wiley eBooks · doi:10.1002/9780470921920.edm079 · Cited by 1
Human Cytochrome P450 Metabolic Activation in Chemical Toxicity
Kim, D., & Chun, Y. (2007) · Toxicological Research · doi:10.5487/tr.2007.23.3.189 · Cited by 1
THE ROLE OF CONSTITUTIVE ANDROSTANE RECEPTOR AND ESTROGEN SULFOTRANSFERASE IN ENERGY HOMEOSTASIS
Gao, J. (2012) · D-Scholarship@Pitt (University of Pittsburgh)
Li, L. (2006) · UKnowledge (University of Kentucky)
Experimental Models of Drug Metabolism and Disposition
Luo, G., Lu, C., Ding, X., & Zhang, D. (2011) · Wiley eBooks · doi:10.1002/9780470929278.ch5
Akingbasote, J. A., Foster, A. J., Sarda, S., Jones, H. B., Wilson, I. D., & Kenna, J. G. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.06.180
“, 2012), toxicokinetic studies and mechanistic studies (Henderson et al., 2003).”
BackgroundMethodInfluentialNEW APPROACHES IN UNDERSTANDING DRUG METABOLISM
Hart, S. N. (2011) · KU ScholarWorks (University of Kansas)
Dose response and potential thresholds in activation and inactivation of procarcinogens.
Henderson, C. J., Paine, M. J. I., Friedberg, T., & Wolf, C. R. (2008)
Self-citationApplication of Humanised and Other Transgenic Models to Predict Human Responses to Drugs
Wolf, C. R., Kapelyukh, Y., Scheer, N., & Henderson, C. J. (2015) · Royal Society of Chemistry eBooks · doi:10.1039/9781782622376-00152
Self-citationFarmakokinetisk betydning av sekvensvarianter i CYP3A4, CYP3A5, POR og PPARA
Dahl, M. (2013) · NORA - Norwegian Open Research Archives
Genetically Humanized Animal Models
Samuelsson, K., Scheer, N., Wilson, I. D., Wolf, C. R., & Henderson, C. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12376-5
Self-citationGrey, A. M. (2012) · TSpace (University of Toronto)
Ho, M. (2011) · TSpace (University of Toronto)
Regulation of the Rat Hepatic NADPH-cytochrome P450 Oxidoreductase by Glucocorticoids
Vonk, A. (2014) · TSpace (University of Toronto)
Tanner, J. (2017) · TSpace (University of Toronto)
Kovalchuk, N. (2017) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/nr3h-bnyc · Cited by 1
Human P450 oxidoreductase deficiency
Pandey, A. V., Barata, I. S., & Flück, C. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00259-4
Cilião, H. L. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Metadata
- Authors
- Henderson, C. J., Otto, D. M. E., Carrie, D., Magnuson, M. A., McLaren, A. W., Rosewell, I., & Wolf, C. R.
- Affiliations
- Cancer Research UK (GB)
- Corresponding author
- Rosewell, Ian
- Wolf, C. Roland
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-04
- Volume
- 278
- Issue
- 15
- Pages
- 13480-13486
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2047821701
- Semantic Scholar
- 23689d9cea73d2a1ad2d52b9778fe58ba7110680
- Cited by
- 258
- References
- 52
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 6 · 2019: 6 · 2018: 7 · 2017: 6 · 2016: 10 · 2015: 15 · 2014: 19 · 2013: 19 · 2012: 25
- FWCI
- 10.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6409 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- NADPH-cytochrome P450 reductase, conditional gene deletion, bile acid synthesis, cholesterol metabolism, acetaminophen metabolism, steroid hormone metabolism
- MeSH terms
- Acetaminophen, Animals, Cytochrome P-450 Enzyme System, Exons, Female, Glutathione, Liver, Male, Mice, Transgenic, NADPH-Ferrihemoprotein Reductase, Pentobarbital, Promoter Regions, Genetic, Serum Albumin, Sex Characteristics, Restriction Mapping, Genomic Library, Gene Deletion, Mice, Knockout, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.